Patients who had surgery for bone and joint infections did just as well with a week or less of antibiotic pills or IV drugs as with the standard four weeks or more, provided antibiotics were also placed directly into the infected area during surgery. The randomized trial, called SOLARIO, was published Sept. 16 in the New England Journal of Medicine and found far fewer side effects in the short-course group.
For patients, the difference is substantial. The median length of treatment after surgery was 6 days in the short group and 42 days in the long group. Symptoms possibly tied to antibiotics were reported by 17.2% of short-course patients at six weeks, compared with 45.2% of those on the longer course.
Bone infections are hard to treat and often follow fractures, joint replacements, or diabetic foot wounds. Weeks of antibiotics can mean IV lines, missed work, diarrhea, and a higher chance of drug-resistant bacteria, so a proven shorter option could change recovery for many people.
Noninferiority Explained in Plain Terms
SOLARIO randomly assigned 500 adults who had surgery for an orthopedic infection at 25 centers in five European countries. Half received seven days or less of systemic antibiotics, meaning pills or IV drugs that travel through the whole body. The other half received four weeks or more.
The trial was designed as a noninferiority study. That means researchers were not trying to prove the short course was better, only that it was not meaningfully worse. Before starting, they set a limit: the short course would pass if its failure rate was no more than 10 percentage points higher than the long course, according to the published trial protocol.
It passed. Definite treatment failure by 12 months occurred in 11.1% of the short-course group and 14.1% of the long-course group, among 475 patients included in the main analysis. An independent committee that did not know which treatment patients received judged whether each case failed.
"Long courses of antibiotics have been preferred in orthopaedics for many years without good evidence that they benefit patients," said Martin McNally of the Oxford Bone Infection Unit, who designed the trial.
The Implanted Antibiotics Behind the Result
The finding depends on one condition: every patient received local antibiotics, delivered by a material implanted at the infection site during surgery that releases the drug directly into bone. The shorter course applies only to that setup, not to bone infections treated without local antibiotics.
Most of those implants came from one company. BONESUPPORT, which makes the CERAMENT line of antibiotic-releasing bone substitutes, said in a release about the study that CERAMENT G was used in 56% of patients and CERAMENT V in 29%, with bone cement-based carriers used in most of the rest. The company has a commercial interest in the result. NEJM lists the European Bone and Joint Infection Society and others as funders, and readers should review the paper's disclosures for full funding and conflict details.
There are other limits. The trial was open label, so patients and doctors knew which treatment was given, though outcome judges did not. It excluded people whose bacteria were resistant to the implanted antibiotic. All sites were in Europe, and the availability and approved uses of specific local antibiotic products differ in the United States.
In plain terms, this was a randomized controlled trial of 500 adults, registered as NCT03806166. It showed that a short course was not worse at preventing treatment failure over one year when local antibiotics were used. It did not show that short courses are safe without local antibiotics or that one implant brand is superior.
Antibiotic resistance adds a public health reason to care. Long courses expose bacteria throughout the body to pressure that can favor resistant strains, and the trial's designers framed shorter treatment as a way to limit side effects, cost, and selection pressure, according to the protocol.
Questions to Ask Before Surgery
The people most affected are adults facing surgery for osteomyelitis, fracture-related infection, infected joint replacements, or deep diabetic foot infections. Older adults and those with kidney problems, who are more vulnerable to antibiotic side effects, may have the most to gain from shorter treatment.
Patients should not stop a prescribed antibiotic course on their own. U.S. guidelines have not changed based on this trial, and the right duration depends on the type of infection, the bacteria involved, and the surgery performed. The findings are best used as a starting point for a conversation with the surgeon and infectious disease team.
Useful questions include whether local antibiotics will be placed during surgery, whether the bacteria are sensitive to them, and whether a shorter systemic course is reasonable. Patients can also ask what side effects to expect and how the team will monitor for recurrence.
Signs of a returning infection include new or worsening pain, redness, swelling, or warmth at the surgical site, wound drainage, or fever. Those should be reported promptly. Severe diarrhea during or after antibiotic treatment can signal C. difficile infection and needs medical attention.
The SOLARIO findings could reshape bone infection care, but uptake will depend on guideline committees, surgeon experience with local antibiotics, and product availability. For now, the bottom line is clear: when antibiotics are implanted during surgery, a week or less of systemic treatment performed as well as a month or more, with far fewer side effects.
Key Questions Answered
What did the SOLARIO trial find? Seven days or less of systemic antibiotics after bone infection surgery was no worse than four weeks or more when local antibiotics were implanted.
How many patients were studied? 500 adults at 25 centers in five European countries, with 475 included in the main analysis.
What does noninferior mean? The short course was shown not to be meaningfully worse than the standard course, within a preset margin of 10 percentage points.
Were there fewer side effects? Yes. At six weeks, 17.2% of short-course patients reported possible antibiotic side effects, compared with 45.2% of long-course patients.
Does this apply to all bone infections? No. It applies to patients who had surgery that included local antibiotics and whose bacteria were not resistant to them.
Should I shorten my antibiotics? No. Do not stop prescribed antibiotics without talking to your care team. U.S. guidelines have not changed.
Is there a conflict of interest? The main implant maker, BONESUPPORT, has promoted the results. Readers should check the NEJM paper's funding and disclosure statements.
Published by Medicaldaily.com
